Benjamin Lightburn News Today

Filament Health Corp. (Cboe CA: FH) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that Chris Wagner has stepped down from his position as Director on the Company's board of directors...

VANCOUVER, BC, April 2, 2024 /CNW/ - Filament Health Corp. , a clinical-stage natural psychedelic drug development company, released its fourth quarter financial results and operational highlights...

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced the appointment of Michael Messinger, CPA, to its Board of Directors (the "Board"). Mr. Messinger will also serve as the Chair of the Company's Audit Committee.

VANCOUVER, BC, Dec. 18, 2023 /CNW/ - Filament Health Corp.  , a clinical‐stage natural psychedelic drug development company, today announced that the special meeting of its securityholders held...

VANCOUVER, BC, Nov. 23, 2023 /CNW/ - Filament Health Corp.  , a clinical–stage natural psychedelic drug development company, today announced that the Company has signed a non-binding term sheet ...

More drugmakers are seeking to harness the medical potential of psychedelics for treating depression, addiction and other hard-to-treat conditions. In this crowded field, Vancouver-based Filament Health has a unique approach:

More drugmakers are seeking to harness the medical potential of psychedelics for treating depression, addiction and other hard-to-treat conditions. In this crowded field, Vancouver-based Filament Health has a unique approach:

A recent boom in psychedelic research has given way to a bumper crop of startups seeking to harness the potential of mind-altering drugs for treating depression, addiction and other conditions.

A recent boom in psychedelic research has given way to a bumper crop of startups seeking to harness the potential of mind-altering drugs for treating depression

By Matthew Perrone | The Associated Press (AP Illustration/Peter Hamlin) (AP) - A recent boom in psychedelic research has given way to a bumper crop of